Implementation needs for expanding oncologist-led germline genetic testing: A qualitative analysis of patients and clinicians.
Abstract
69 Background: Germline genetic testing (gGT) is increasingly important in oncology, enabling intensified surveillance and risk-reducing strategies for high-risk individuals and targeted therapies for patients with cancer. As testing eligibility expands, mainstream gGT by non-geneticist clinicians is being adopted in oncology clinics. We sought to identify knowledge gaps and implementation needs in oncologist-led gGT. Methods: We conducted semi-structured interviews with 14 clinicians (8 medical oncologists, 2 surgical oncologists, 4 genetic counselors) at New York-Presbyterian Columbia and Hudson Valley, and 26 English- and Spanish- speaking patients with breast, ovarian, pancreatic, or prostate cancer who had undergone gGT within the last 5 years (10 pathogenic variants, 9 variants of uncertain significance [VUS], 7 negative). Interviews were transcribed verbatim, coded in Dedoose, and analyzed using reflexive thematic analysis. Results: Clinicians and patients reported that oncologist-led gGT improved access to testing, expedited treatment planning, and reduced appointment burden. But two key areas for improvement emerged. First, communication about implications beyond immediate cancer treatment was often limited. While most oncologists were comfortable discussing treatment-related implications, such as eligibility for PARP inhibitors or contralateral prophylactic mastectomy, discussions of enhanced cancer surveillance and cascade testing were less consistent. Correspondingly, patients accurately described whether their genetic test results had any impact on their cancer care, however, few described broader implications for cancer surveillance for themselves or family members. Many patients described cognitive overload during initial oncology visits and prioritized understanding cancer treatment plans over seeking clarification about their gGT results. Second, challenges were identified in understanding and communicating VUS results. Oncologists lacked a consistent workflow for tracking VUS reclassifications and were uncertain how to comprehensively describe VUS results to patients. While patients understood that VUS results did not alter management, few knew VUS results can be reclassified over time. Multiple patients confused VUS with benign results. Conclusions: Oncologist-led gGT has important benefits including expedited testing and more efficient treatment planning. However, improvements are needed in communication about implications beyond immediate cancer management and in education regarding VUS results. Potential strategies include emphasizing access to post-test genetic counseling, revisiting genetic information across multiple visits, especially after completion of cancer treatment, and implementing standardized protocols for VUS communication and reclassification follow-up.